GlassScriptPhysician profile
Jorge L Acosta
NPI 1013960772
$11,192.19
in general payments reported to CMS, 2019-2025
30 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 93% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,909 · 2020: $1,754 · 2021: $1,934 · 2022: $1,361 · 2023: $1,394 · 2024: $1,652 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,902 · Education: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.47 |
| Education | $330.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,347.41 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $1,386.69 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,048.89 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $780.13 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $775.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $606.06 | 2019-2022 | |
| Lilly USA, LLC | $512.36 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Amarin Pharma, INC. | $500.77 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $453.16 | 2019-2021 | |
| Novo Nordisk INC | $426.83 | 2019-2025 | |
| Pfizer INC. | $420.95 | 2019-2025 | |
| Allergan, INC. | $402.47 | 2020 | |
| Abbvie INC. | $379.89 | 2020-2025 | Qulipta, Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $184.24 | 2019-2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $183.98 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $164.41 | 2021-2025 | |
| Ardelyx, INC. | $100.59 | 2024 | Ibsrela |
| Amgen INC. | $98.03 | 2023-2025 | Repatha, Otezla, Repatha |
| Avanir Pharmaceuticals, INC. | $70.66 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $63.43 | 2021-2023 | |
| Horizon Therapeutics Plc | $49.73 | 2020-2021 | |
| Dexcom, INC. | $47.92 | 2022-2023 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $45.13 | 2022 | |
| Ironwood Pharmaceuticals, INC | $30.31 | 2020 | |
| Abbott Laboratories | $23.03 | 2023 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $20.68 | 2024 | Nuedexta |
| Sumitomo Pharma America, INC. | $19.26 | 2025 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $18.57 | 2019 | |
| Merck Sharp & Dohme LLC | $17.73 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.23 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Acosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.